| Business Summary | | ImmuLogic
Pharmaceutical
Corporation
is
a
biopharmaceutical
company.
On
March
23
1999,
the
Board
of
Directors
approved
a
plan
to
liquidate
and
dissolve
the
Company.
The
plan
was
approved
by
a
majority
of
the
stockholders
of
the
Company
on
August
25,
1999.
ImmuLogic's
material
proprietary
rights
consisted
of
patents
and
licenses
to
patents
in
the
following
areas:
general
immunotherapy
and
autoimmune,
allergy
and
drug
abuse
therapy.
The
Company's
rights
relating
to
general
immunotherapy
were
licensed
from
Washington
University
and
the
Massachusetts
Institute
of
Technology
(MIT).
The
licenses
from
Washington
University
and
MIT
terminated
in
1999.
The
Company's
patents
relating
to
allergy
therapy
were
transferred
to
Heska
Corporation
in
1999.
The
Company's
patents
relating
to
drug
abuse
therapy
were
sold
to
Cantab
Pharmaceuticals
plc
on
February
2,
1999. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IMUL
is
a
biopharmaceutical
company
that
develops
products
to
treat
allergies
and
autoimmune
diseases.
In
1999,
the
Company
approved
a
plan
to
liquidate
and
dissolve
its
assets.
For
the
six
months
ended
6/30/99,
revenues
increased
13%
to
$1.1
million.
Net
loss
increased
9%
to
$2.1
million.
Revenues
reflect
research
and
development
services
performed
for
Cantab
Pharmaceuticals.
Higher
loss
reflects
the
inclusion
of
a
$966
thousand
loss
on
leasehold
improvements. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999 Pay | |
| J. Richard Crowley, 44 Pres,
Sec. and Treasurer | $220K | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|